Research ArticleMetabolism, Transport, and Pharmacogenomics
Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases
Shruthi Vaidhyanathan, Brynna Wilken-Resman, Daniel J. Ma, Karen E. Parrish, Rajendar K. Mittapalli, Brett L. Carlson, Jann N. Sarkaria and William F. Elmquist
Journal of Pharmacology and Experimental Therapeutics February 2016, 356 (2) 251-259; DOI: https://doi.org/10.1124/jpet.115.229393
Shruthi Vaidhyanathan
Department of Pharmaceutics, Brain Barriers Research Center, University of Minnesota, Minneapolis, Minnesota (S.V., B.W.-R., K.E.P., R.K.M., W.F.E.); and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (D.J.M, B.L.C., J.N.S.)
Brynna Wilken-Resman
Department of Pharmaceutics, Brain Barriers Research Center, University of Minnesota, Minneapolis, Minnesota (S.V., B.W.-R., K.E.P., R.K.M., W.F.E.); and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (D.J.M, B.L.C., J.N.S.)
Daniel J. Ma
Department of Pharmaceutics, Brain Barriers Research Center, University of Minnesota, Minneapolis, Minnesota (S.V., B.W.-R., K.E.P., R.K.M., W.F.E.); and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (D.J.M, B.L.C., J.N.S.)
Karen E. Parrish
Department of Pharmaceutics, Brain Barriers Research Center, University of Minnesota, Minneapolis, Minnesota (S.V., B.W.-R., K.E.P., R.K.M., W.F.E.); and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (D.J.M, B.L.C., J.N.S.)
Rajendar K. Mittapalli
Department of Pharmaceutics, Brain Barriers Research Center, University of Minnesota, Minneapolis, Minnesota (S.V., B.W.-R., K.E.P., R.K.M., W.F.E.); and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (D.J.M, B.L.C., J.N.S.)
Brett L. Carlson
Department of Pharmaceutics, Brain Barriers Research Center, University of Minnesota, Minneapolis, Minnesota (S.V., B.W.-R., K.E.P., R.K.M., W.F.E.); and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (D.J.M, B.L.C., J.N.S.)
Jann N. Sarkaria
Department of Pharmaceutics, Brain Barriers Research Center, University of Minnesota, Minneapolis, Minnesota (S.V., B.W.-R., K.E.P., R.K.M., W.F.E.); and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (D.J.M, B.L.C., J.N.S.)
William F. Elmquist
Department of Pharmaceutics, Brain Barriers Research Center, University of Minnesota, Minneapolis, Minnesota (S.V., B.W.-R., K.E.P., R.K.M., W.F.E.); and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (D.J.M, B.L.C., J.N.S.)

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleMetabolism, Transport, and Pharmacogenomics
GSK2126458 Distribution to the Brain
Shruthi Vaidhyanathan, Brynna Wilken-Resman, Daniel J. Ma, Karen E. Parrish, Rajendar K. Mittapalli, Brett L. Carlson, Jann N. Sarkaria and William F. Elmquist
Journal of Pharmacology and Experimental Therapeutics February 1, 2016, 356 (2) 251-259; DOI: https://doi.org/10.1124/jpet.115.229393
Research ArticleMetabolism, Transport, and Pharmacogenomics
GSK2126458 Distribution to the Brain
Shruthi Vaidhyanathan, Brynna Wilken-Resman, Daniel J. Ma, Karen E. Parrish, Rajendar K. Mittapalli, Brett L. Carlson, Jann N. Sarkaria and William F. Elmquist
Journal of Pharmacology and Experimental Therapeutics February 1, 2016, 356 (2) 251-259; DOI: https://doi.org/10.1124/jpet.115.229393